About NeurAegis
NeurAegis is a preclinical stage neuropharmaceutical company pioneering the development of breakthrough treatments for neurological disorders including concussion and epilepsy. Founded in 2016, our initial focus is developing first-in-class, novel protease inhibitors for mild traumatic brain injury (concussion) where there are currently no FDA approved treatments.
For more information, follow us on LinkedIn.
Press Release
NeurAegis Scientific Founder Michel Baudry Awarded $3.8M Grant from the Department of Defense to Advance Product Candidate for Treating Traumatic Brain Injury and Concussion
Proven Leadership
NeurAegis is led by a team with deep, relevant experience for developing novel therapeutics.
Michel Baudry, PhD
Chief Scientific Officer
Joe Blanchard, MBA
President and Chief Executive Officer
Mike Palfreyman, PhD
Drug Development Advisor